Aug 2026· Brain Science· Vol 16· 0 citations· 26 references
Medicine
TL;DR
The present review suggests that LAIs may represent a valuable therapeutic strategy for patients with schizophrenia and comorbid SUD, although the available evidence remains heterogeneous in terms of study design, patient populations, and outcome measures.
Abstract
Highlights What are the main findings? Nine studies involving 2062 patients with schizophrenia and comorbid substance use disorder (SUD) were included, with follow-up periods ranging from 6 months to 3 years. Several studies reported favorable clinical outcomes with long-acting injectable (LAI) antipsychotics, but the evidence was mixed and did not consistently demonstrate superiority over oral antipsychotics. What are the implications of the main findings? LAI antipsychotics may be a valuable treatment option for patients with schizophrenia and comorbid SUD, particularly where adherence to oral medication is a concern. The heterogeneity of the available evidence highlights the need for more high-quality, standardized research to better establish the efficacy, effectiveness, and safety of LAIs in this patient population. Abstract Background/Objectives: The aim of this systematic review is to assess the efficacy, effectiveness, and safety of LAI antipsychotics in patients with schizophrenia and comorbid SUD, providing useful information for clinical decision making and guiding future research in the management of this complex patient population. Methods: The search was conducted on 1 July 2026 and produced 87 results in total; after the screening process, 78 articles were excluded based on the predefined eligibility criteria. The full texts of the remaining 9 studies were retrieved and thoroughly evaluated for inclusion in the qualitative synthesis. Results: The 9 articles that met the criteria for inclusion included 2062 patients in total with follow-up periods varying between 6 months and 3 years. Several studies reported favorable clinical outcomes associated with LAIs; however, not all studies demonstrated clear superiority of LAIs over oral antipsychotics. Conclusions: The present review suggests that LAIs may represent a valuable therapeutic strategy for patients with schizophrenia and comorbid SUD, although the available evidence remains heterogeneous in terms of study design, patient populations, and outcome measures.
LAIAs were associated with substantially less health care utilization and fewer relapses of manic and mixed episodes, and they were not associated with increased risk of nonpsychiatric hospitalizations, notably for cardiovascular disease.
Eunice Kehui Deng, Caige Huang, V. Yan et al.· American Journal of Psychiat...· 0 citations
INTRODUCTION
Long-acting injectable antipsychotics (LAIs) are underused despite known benefits. This subgroup analysis from the Attitudes DriVing regional differences in LAI ANtipsychotic utilization for schizophrenia among healthcare professionals (HCPs), patients, and CaregivErs (ADVANCE) study aimed to understand fa...
K. R. Franzenburg, Rolf T. Hansen, M. Suett et al.· Psychiatry Research· 0 citations
ObjectiveDescribe concurrent use of two long-acting injectable (LAI) antipsychotics in selected patients with treatment-resistant schizophrenia and persistent aggression at a forensic health facility. Evidence remains limited for this off-licence strategy.MethodsRetrospective case series conducted at a specialist foren...
A. Rodrigo, Jacques Claassen, Daveena Mawren· Australasian Psychiatry· 0 citations
AIMDs remain common among individuals with SMI in African settings, affecting nearly one-third of treated patients and underscore the continued clinical burden of AIMDs and the need for cautious prescribing, routine monitoring, and integrated management of modifiable risk factors, including substance use.
Abstract Background A study of the efficacy of clozapine and atypical antipsychotics in patients with treatment-resistant schizophrenia comorbid with addictions is relevant for improving the clinical prognosis of this disease. Aims & Objectives To evaluate the clinical efficacy of combination therapy with clozapine and...
G. Selivanov, N. Bokhan, T. Shushpanova et al.· International Journal of Neu...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.